These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 20177404)

  • 41. Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond.
    Wong HL; Christie M; Gately L; Tie J; Lee B; Semira C; Lok SW; Wong R; Gibbs P
    Future Oncol; 2018 Nov; 14(26):2725-2739. PubMed ID: 30004261
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.
    Niessen RC; Berends MJ; Wu Y; Sijmons RH; Hollema H; Ligtenberg MJ; de Walle HE; de Vries EG; Karrenbeld A; Buys CH; van der Zee AG; Hofstra RM; Kleibeuker JH
    Gut; 2006 Dec; 55(12):1781-8. PubMed ID: 16636019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on Hereditary Colorectal Cancer.
    DA Silva FC; Wernhoff P; Dominguez-Barrera C; Dominguez-Valentin M
    Anticancer Res; 2016 Sep; 36(9):4399-405. PubMed ID: 27630275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
    Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
    Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 47. From Genetics to Histomolecular Characterization: An Insight into Colorectal Carcinogenesis in Lynch Syndrome.
    Lepore Signorile M; Disciglio V; Di Carlo G; Pisani A; Simone C; Ingravallo G
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications.
    Bonis PA; Trikalinos TA; Chung M; Chew P; Ip S; DeVine DA; Lau J
    Evid Rep Technol Assess (Full Rep); 2007 May; (150):1-180. PubMed ID: 17764220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lynch syndrome: a pediatric perspective.
    Huang SC; Durno CA; Erdman SH
    J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):144-52. PubMed ID: 24051481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis.
    Tricarico R; Cortellino S; Riccio A; Jagmohan-Changur S; Van der Klift H; Wijnen J; Turner D; Ventura A; Rovella V; Percesepe A; Lucci-Cordisco E; Radice P; Bertario L; Pedroni M; Ponz de Leon M; Mancuso P; Devarajan K; Cai KQ; Klein-Szanto AJ; Neri G; Møller P; Viel A; Genuardi M; Fodde R; Bellacosa A
    Oncotarget; 2015 Dec; 6(40):42892-904. PubMed ID: 26503472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
    Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
    Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
    Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
    Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Translating colorectal cancer genetics into clinically useful biomarkers.
    Morley-Bunker A; Walker LC; Currie MJ; Pearson J; Eglinton T
    Colorectal Dis; 2016 Aug; 18(8):749-62. PubMed ID: 26990814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HEREDITARY, SPORADIC AND METASTATIC COLORECTAL CANCER ARE COMMONLY DRIVEN BY SPECIFIC SPECTRUMS OF DEFECTIVE DNA MISMATCH REPAIR COMPONENTS.
    Carethers JM
    Trans Am Clin Climatol Assoc; 2016; 127():81-97. PubMed ID: 28066040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploiting DNA mismatch repair deficiency as a therapeutic strategy.
    Guillotin D; Martin SA
    Exp Cell Res; 2014 Nov; 329(1):110-5. PubMed ID: 25017099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X.
    Lindor NM; Rabe K; Petersen GM; Haile R; Casey G; Baron J; Gallinger S; Bapat B; Aronson M; Hopper J; Jass J; LeMarchand L; Grove J; Potter J; Newcomb P; Terdiman JP; Conrad P; Moslein G; Goldberg R; Ziogas A; Anton-Culver H; de Andrade M; Siegmund K; Thibodeau SN; Boardman LA; Seminara D
    JAMA; 2005 Apr; 293(16):1979-85. PubMed ID: 15855431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma.
    Shia J
    Semin Diagn Pathol; 2015 Sep; 32(5):352-61. PubMed ID: 25716099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of Lynch syndrome among patients with colorectal cancer.
    Moreira L; Balaguer F; Lindor N; de la Chapelle A; Hampel H; Aaltonen LA; Hopper JL; Le Marchand L; Gallinger S; Newcomb PA; Haile R; Thibodeau SN; Gunawardena S; Jenkins MA; Buchanan DD; Potter JD; Baron JA; Ahnen DJ; Moreno V; Andreu M; Ponz de Leon M; Rustgi AK; Castells A;
    JAMA; 2012 Oct; 308(15):1555-65. PubMed ID: 23073952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations.
    Egoavil CM; Montenegro P; Soto JL; Casanova L; Sanchez-Lihon J; Castillejo MI; Martinez-Canto A; Perez-Carbonell L; Castillejo A; Guarinos C; Barbera VM; Jover R; Paya A; Alenda C
    Pathology; 2011 Apr; 43(3):228-33. PubMed ID: 21436632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.